XML 50 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-based Compensation - Stock option activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Options    
Outstanding as of December 31, 2022 3,356,937  
Sesen Bio options assumed in the Merger 765,223  
Granted 144,352  
Forfeited (82,427)  
Expired (38)  
Outstanding as of March 31, 2023 4,184,047  
Exercisable as of March 31, 2023 3,015,084  
Vested and expected to vest at March 31, 2023 4,184,047  
Weighted average exercise price    
Outstanding as of December 31, 2022 (in USD per share) $ 1.01  
Sesen Bio options assumed in the Merger (in USD per share) 27.94  
Granted (in USD per share) 5.64  
Forfeited (in USD per share) 1.46  
Expired (in USD per share) 1.46  
Outstanding as of March 31, 2023 (in USD per share) 6.11  
Exercisable as of March 31, 2023 (in USD per share) 5.58  
Vested and expected to vest at March 31, 2023 (in USD per share) 6.11  
Share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value $ 2.64 $ 0.75
Weighted average remaining contractual term (years)    
Outstanding as of March 31, 2023 5 years 10 months 24 days  
Exercisable as of March 31, 2023 3 years 7 months 6 days  
Vested and expected to vest at March 31, 2023 5 years 10 months 24 days  
Aggregate Intrinsic Value    
Outstanding as of March 31, 2023 $ 6,798  
Exercisable as of March 31, 2023 5,057  
Vested and expected to vest at March 31, 2023 $ 6,798